NASDAQ: NVAX · Life Sciences · 3 alerts · CIK 1000694
Share price
$8.06Close, Nov 16
Market cap
$1.33B
Shares outstanding
165.01MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Novavax Inc filings on SEC EDGAR ↗
Novavax reported total revenue of $68.3 million for the third quarter of 2026, a slight decrease from $70.4 million in the prior year, while net loss narrowed significantly to $31.4 million compared to $202.4 million. For the nine-month period, the company experienced a net loss of $94.3 million, a sharp reversal from the $422.8 million net income recorded in the same period of 2025, primarily due to a substantial drop in product sales and licensing revenue.
Novavax reported Q3 2026 total revenue of $68 million and raised its full-year 2026 revenue guidance to $400 million at the mid-point. The company also earned a $125 million milestone payment from partner Sanofi following the initiation of a Phase 3 combination vaccine trial in Europe.
“This quarter, we continued to execute across all three pillars of our strategy. Our partner Sanofi initiated their Phase 3 influenza-COVID-19 combination vaccine trial vaccine trial in Europe, triggering a $125 million milestone payment. Our focused R&D efforts are building a growing body of data on what our technology can do in infectious disease, advancing our C. difficile candidate towards the clinic and exploring oncology as a potential new area of application. And we have been doing this while continuing to reduce expenses and operate with financial discipline. Over time, we believe this strategy can build a robust and profitable Novavax, with multiple partners and products, diversified revenue streams and a meaningful impact on global health.”
John C. Jacobs, President and Chief Executive Officer, Novavax